Neurologic Manifestations and Complications of COVID-19

Hensley, M.; Markantone, Desiree M.; Prescott, Hallie C.

doi:10.1146/annurev-med-042320-010427

Cited by 27 publications

(24 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over time, a wide variety of central and/or peripheral nervous manifestations of COVID-19, such as headache, dizziness, sleep disorders, anosmia and dysgeusia, impaired consciousness, cerebrovascular disorders (including ischemic stroke and macro/microhemorrhages), encephalopathies, immune-mediated complications (Guillain-Barré syndrome and acute disseminated encephalomyelitis), seizures, psychosis, anxiety/depression, and psychological distress have been notified. It is estimated that during the acute phase of COVID-19 about one-third of patients develop neuropsychiatric symptoms ( Helms et al, 2020 ; Hensley et al, 2022 ; Romero-Sánchez et al, 2020 ; Xu et al, 2021 ; Zawilska et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Psychiatric and neurological complications of long COVID

Zawilska

Kuczyńska

2022

Journal of Psychiatric Research

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Psychiatric and neurological complications of long COVID

Zawilska

Kuczyńska

2022

Journal of Psychiatric Research

View full text Add to dashboard Cite

“…SARS-CoV-2 is the cause for human coronavirus disease 2019 (COVID-19), a severe, life-threatening illness; as of March 2022, there have been more than 460 million cases worldwide, more than 6 million of which have been fatal ( https://covid19.who.int/ ). COVID-19 is mainly a respiratory disease, yet neurological signs and symptoms such as stroke, seizures, and altered mental status have been reported in more than a third of patients during the acute phase of COVID-19 ( 1 – 3 ). Furthermore, about 10–30% of patients develop persistent symptoms and / or delayed or long-term complications following acute COVID-19; a syndrome including diverse neuropsychiatric sequelae, that has been called long COVID or post-acute COVID-19 ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Young COVID-19 Patients Show a Higher Degree of Microglial Activation When Compared to Controls

et al. 2022

View full text Add to dashboard Cite

The severe acute respiratory syndrome-corona virus type 2 (SARS-CoV-2) is the cause of human coronavirus disease 2019 (COVID-19). Since its identification in late 2019 SARS-CoV-2 has spread rapidly around the world creating a global pandemic. Although considered mainly a respiratory disease, COVID-19 also encompasses a variety of neuropsychiatric symptoms. How infection with SARS-CoV-2 leads to brain damage has remained largely elusive so far. In particular, it has remained unclear, whether signs of immune cell and / or innate immune and reactive astrogliosis are due to direct effects of the virus or may be an expression of a non-specific reaction of the brain to a severe life-threatening disease with a considerable proportion of patients requiring intensive care and invasive ventilation activation. Therefore, we designed a case-control-study of ten patients who died of COVID-19 and ten age-matched non-COVID-19-controls to quantitatively assess microglial and astroglial response. To minimize possible effects of severe systemic inflammation and / or invasive therapeutic measures we included only patients without any clinical or pathomorphological indication of sepsis and who had not been subjected to invasive intensive care treatment. Our results show a significantly higher degree of microglia activation in younger COVID-19 patients, while the difference was less and not significant for older COVID-19 patients. The difference in the degree of reactive gliosis increased with age but was not influenced by COVID-19. These preliminary data warrants further investigation of larger patient cohorts using additional immunohistochemical markers for different microglial phenotypes.

show abstract

“…Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes human coronavirus disease 2019 (COVID-19) with multi-system effects that include neurological, vascular and neurovascular injury. Acute neurological sequelae are common, ranging from mild dizziness, headaches and anosmia to severe encephalitis, stroke and delirium (Chen et al, 2020; Hensley et al, 2021; Paterson et al, 2020; Zubair et al, 2020). These sequelae may arise from systemic physiological insults (e.g.…”

Section: Introductionmentioning

confidence: 99%

Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study

Tsvetanov

Spindler

Stamatakis

et al. 2022

Preprint

View full text Add to dashboard Cite

Human coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has multiple neurological consequences, but its long-term effect on brain health is still uncertain. The cerebrovascular consequences of COVID-19 may also affect brain health. Here we assess cerebrovascular health in 45 hospitalised patients using the resting state fluctuation amplitudes (RSFA) from functional magnetic resonance imaging, in relation to disease severity and in contrast with 42 controls. Widespread changes in frontoparietal RSFA were related to the severity of the acute COVID-19 episode, as indexed by COVID-19 WHO Progression Scale, inflammatory and coagulatory biomarkers. This relationship was not explained by chronic cardiorespiratory dysfunction, age, or sex. Exploratory analysis suggests that the level of cerebrovascular dysfunction is associated with cognitive, mental, and physical health at follow-up. The principal findings were consistent across univariate and multivariate approaches. The results indicate chronic cerebrovascular impairment following severe acute COVID-19, with the potential for long-term consequences on cognitive function and mental wellbeing.

show abstract

Neurologic Manifestations and Complications of COVID-19

Cited by 27 publications

References 96 publications

Psychiatric and neurological complications of long COVID

Psychiatric and neurological complications of long COVID

Young COVID-19 Patients Show a Higher Degree of Microglial Activation When Compared to Controls

Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study

Contact Info

Product

Resources

About